Plasminogen lysine-binding sites (LBS) (LBS)

Plasminogen lysine-binding sites (LBS) are specialized structural motifs located within the kringle domains of the plasminogen molecule, specifically K1, K2, K4, and K5 (UniProt: P00747). These sites are essential for the regulation of fibrinolysis, as they mediate the high-affinity binding of plasminogen and its active form, plasmin, to C-terminal lysine residues on fibrin clots and cell surface receptors (PubMed: 11031122). This interaction facilitates the localization of plasminogen to the fibrin matrix, where it is efficiently converted to plasmin by activators like tPA, leading to clot dissolution. In pathological states, excessive fibrinolysis can lead to severe hemorrhage, making the LBS a critical therapeutic target. Antifibrinolytic drugs, such as tranexamic acid and aminocaproic acid, function as lysine analogs that competitively bind to these sites (StatPearls: NBK532909). By blocking the LBS, these agents prevent the association of plasminogen with fibrin, thereby stabilizing the clot and reducing bleeding. Consequently, targeting the LBS is a standard clinical strategy for managing trauma-induced coagulopathy, surgical bleeding, and heavy menstrual cycles.

Other names

Kringle domainsLysine-binding pocketsPlasminogen LBS

Antifibrinolytic drugs like tranexamic acid and aminocaproic acid act as lysine analogs that competitively bind to the lysine-binding sites on plasminogen. This prevents the binding of plasminogen to fibrin, thereby inhibiting its conversion to plasmin and subsequent fibrin degradation.